References
Arnon SS, Schechter R, Inglesby TV, Henderson DA, Bartlett JG, Ascher MS, Eitzen E, Fine AD, Hauer J, Layton M, Lillibridge S, Osterholm MT, O’Toole T, Parker G, Perl TM, Russell PK, Swerdlow DL, Tonat K, Working Group on Civilian Biodefense (2001) Botulinum toxin as a biological weapon: medical and public health management. JAMA 285(8):1059–1070. https://doi.org/10.1001/jama.285.8.1059
Bird AM, Smith TL, Walton AE (2011) Current treatment strategies for clozapine-induced sialorrhea. Ann Pharmacother 45(5):667–675. https://doi.org/10.1345/aph.1P761
Kahl KG, Hagenah J, Zapf S, Trillenberg P, Klein C, Lencer R (2004) Botulinum toxin as an effective treatment of clozapine-induced hypersalivation. Psychopharmacology 173(1–2):229–230. https://doi.org/10.1007/s00213-004-1803-0
Kahl KG, Trillenberg P, Kordon A, Lencer R, Klein C, Hagenah J (2005) Pharmacological strategies for clozapine-induced hypersalivation: treatment with botulinum toxin B in one patient and review of the literature. Nervenarzt 76(2):205–208. https://doi.org/10.1007/s00115-004-1800-x
Lakraj AA, Moghimi N, Jabbari B (2013) Sialorrhea: anatomy, pathophysiology and treatment with emphasis on the role of botulinum toxins. Toxins (Basel) 5(5):1010–1031. https://doi.org/10.3390/toxins5051010
Maher S, Cunningham A, O'Callaghan N, Byrne F, Mc Donald C, McInerney S, Hallahan B (2016) Clozapine-induced hypersalivation: an estimate of prevalence, severity and impact on quality of life. Ther Adv Psychopharmacol 6(3):178–184. https://doi.org/10.1177/2045125316641019
Marks L, Weinreich J (2001) Drooling in Parkinson’s disease: a novel tool for assessment of swallow frequency. Int J Lang Commun Disord 36(s1):288–291. https://doi.org/10.3109/13682820109177899
Nielsen J, Dahm M, Lublin H, Taylor D (2010) Psychiatrists’ attitude towards and knowledge of clozapine treatment. J Psychopharmacol 24(7):965–971. https://doi.org/10.1177/0269881108100320
Pal PK, Calne DB, Calne S, Tsui JK (2000) Botulinum toxin A as treatment for drooling saliva in PD. Neurology 54(1):244–247. https://doi.org/10.1212/WNL.54.1.244
Steinlechner S, Klein C, Moser A, Lencer R, Hagenah J (2010) Botulinum toxin B as an effective and safe treatment for neuroleptic-induced sialorrhea. Psychopharmacology 207(4):593–597. https://doi.org/10.1007/s00213-009-1689-y
Thomas-Stonell N, Greenberg J (1988) Three treatment approaches and clinical factors in the reduction of drooling. Dysphagia 3(2):73–78. https://doi.org/10.1007/BF02412423
Vashishta R, Nguyen SA, White DR, Gillespie MB (2013) Botulinum toxin for the treatment of sialorrhea: a meta-analysis. Otolaryngol Head Neck Surg 148(2):191–196. https://doi.org/10.1177/0194599812465059
Yesilyurt S, Aras I, Altinbas K, Atagun MI, Kurt E (2010) Pathophysiology of clozapine induced sialorrhea and current treatment choices. Düşünen Adam 23(4):275–281
Yusufi B, Mukherjee S, Flanagan R, Paton C, Dunn G, Page E, Barnes TR (2007) Prevalence and nature of side effects during clozapine maintenance treatment and the relationship with clozapine dose and plasma concentration. Int Clin Psychopharmacol 22(4):238–243. https://doi.org/10.1097/YIC.0b013e32819f8f17
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Verma, R., Anand, K.S. Botulinum toxin: a novel therapy for clozapine-induced sialorrhoea. Psychopharmacology 235, 369–371 (2018). https://doi.org/10.1007/s00213-017-4795-2
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00213-017-4795-2